Jordan Berlin

Also affiliated with Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v1

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Papers

Driven by 27 papers — median percentile 0. Top paper: “Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS -mutant Melanoma”.

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS -mutant Melanoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3872

N/A

1.6DataRank · unranked

44 citations

Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow +10 more

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

New England Journal of Medicine(2004)10.1056/nejmoa032691

N/A

1.4DataRank · unranked

10954 citations

Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim +18 more

Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab

Clinical Colorectal Cancer(2020)10.1016/j.clcc.2020.02.006

N/A

0DataRank · unranked

25 citations

Audrey Allen, Jordan Berlin, Satya Das

Validating enhancer signature classifications (ESCs) in pancreatic neuroendocrine tumors (PNETs).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.627

N/A

0DataRank · unranked

0 citations

Chanjuan Shi, Jordan Berlin, Satya Das, Vincent Quoc‐Huy Trinh

Faculty Opinions recommendation of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature(2020)10.3410/f.735889867.793571321

N/A

0DataRank · unranked

0 citations

Jordan Berlin

Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer

The Oncologist(2021)10.1002/onco.13741

N/A

0DataRank · unranked

48 citations

Subir Goyal, Yoanna S Pumpalova, Mohamad Bassam Sonbol, Satya Das, Sigurdís Haraldsdóttir +10 more

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1789

N/A

0DataRank · unranked

53 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer

Journal of Nuclear Medicine(2021)10.2967/jnumed.120.261594

N/A

0DataRank · unranked

30 citations

Joe Grudzinski, Gary T. Smith, Todd E. Peterson, Jennifer G. Whisenant, Tiffany L. Hickman +9 more

Racial disparity in taxane‐induced neutropenia among cancer patients

Cancer Medicine(2021)10.1002/cam4.4181

N/A

0DataRank · unranked

9 citations

Fei Wang, Rajiv Agarwal, Robert J. Carroll, Wei‐Qi Wei, Jordan Berlin +2 more

A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.363

N/A

0DataRank · unranked

1 citations

Liping Du, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah +9 more

Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4109

N/A

0DataRank · unranked

0 citations

Aman Chauhan, Liping Du, Katharine Thomas, Aasems Jacob, Aimee Schad +13 more

Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma

Clinical Colorectal Cancer(2022)10.1016/j.clcc.2022.03.003

N/A

0DataRank · unranked

12 citations

Jill Gilbert, Jennifer G. Whisenant, Gregory D. Ayers, Florencia G. Jalikis, Kimberly B. Dahlman +5 more

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3334

N/A

0DataRank · unranked

59 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Factors and Barriers to Goals-of-Care Conversations for Patients With Cancer and Inpatient Mortality

JCO Oncology Practice(2023)10.1200/op.23.00095

N/A

0DataRank · unranked

8 citations

Julie Jiyun Lee, Henry J. Domenico, Barbara J. Martin, Marc Bennett, Sara Martin +4 more

Correlates of Taxane-Induced Neuropathy, an Electronic Health Record Based Observational Study

Cancers(2023)10.3390/cancers15030754

N/A

0DataRank · unranked

7 citations

Neil S. Zheng, Rajiv Agarwal, Robert J. Carroll, Samuel M. Rubinstein, Karen M. Winkfield +4 more

A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4044

N/A

0DataRank · unranked

4 citations

Heloisa P. Soares, Farshid Dayyani, Anwaar Saeed, Edward S. Kim, Ning Jin +7 more

Data from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

(2023)10.1158/1078-0432.c.6532311

N/A

0DataRank · unranked

0 citations

Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow +10 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v1

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors

(2023)10.1158/1078-0432.c.6519480

N/A

0DataRank · unranked

0 citations

Wooin Lee, Alice P. Chen, M. Wade Calcutt, David L. Hachey, W. Vermeulen +6 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176.v1

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v2

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Circulating microRNAs in association with pancreatic cancer risk within 5 years

International Journal of Cancer(2024)10.1002/ijc.34956

N/A

0DataRank · unranked

11 citations

Hui Cai, Qiuyin Cai, Jie Wu, Rachael Z. Stolzenberg‐Solomon, Xingyi Guo +8 more

Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3133

N/A

0DataRank · unranked

16 citations

Seong-Woo Bae, Jennifer G. Whisenant, Gregory D. Ayers, Quanhu Sheng, Todd E. Peterson +15 more

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer

The Oncologist(2025)10.1093/oncolo/oyaf400

N/A

0DataRank · unranked

0 citations

Shannon Stockton, Heloisa P. Soares, Farshid Dayyani, Anwaar Saeed, Edward Kim +12 more

Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer

Translational Oncology(2020)10.1016/j.tranon.2020.100828

N/A

0DataRank · unranked

48 citations

Ling Geng, Ping Zhao, Allie Fu, M. Schulte, Ramona Graves‐Deal +5 more

Jordan Berlin

Indexed papers

Top data-sharing exemplar

Papers